In the present study, sodium selenate was found to result in a significant decline in tau phosphorylation at pS422 and pS396 in N2aSW cells, indicating that selenate may also implement its effect on AD model cells through the PP2A-mediated pathway. This evidence concerns the gene MAPT and Alzheimer disease.